CA2529507C - Compounds and methods for inducing apoptosis in cancer cells - Google Patents

Compounds and methods for inducing apoptosis in cancer cells Download PDF

Info

Publication number
CA2529507C
CA2529507C CA2529507A CA2529507A CA2529507C CA 2529507 C CA2529507 C CA 2529507C CA 2529507 A CA2529507 A CA 2529507A CA 2529507 A CA2529507 A CA 2529507A CA 2529507 C CA2529507 C CA 2529507C
Authority
CA
Canada
Prior art keywords
cancer
bcl
compounds
compound
gallate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2529507A
Other languages
English (en)
French (fr)
Other versions
CA2529507A1 (en
Inventor
John C. Reed
Maurizio Pellecchia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Publication of CA2529507A1 publication Critical patent/CA2529507A1/en
Application granted granted Critical
Publication of CA2529507C publication Critical patent/CA2529507C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2529507A 2003-06-25 2004-06-25 Compounds and methods for inducing apoptosis in cancer cells Expired - Fee Related CA2529507C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48288603P 2003-06-25 2003-06-25
US60/482,886 2003-06-25
PCT/US2004/020569 WO2005009434A2 (en) 2003-06-25 2004-06-25 Compounds and methods for inducing apoptosis in cancer cells

Publications (2)

Publication Number Publication Date
CA2529507A1 CA2529507A1 (en) 2005-02-03
CA2529507C true CA2529507C (en) 2011-08-09

Family

ID=34102647

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2529507A Expired - Fee Related CA2529507C (en) 2003-06-25 2004-06-25 Compounds and methods for inducing apoptosis in cancer cells

Country Status (13)

Country Link
US (3) US7812058B2 (https=)
EP (2) EP1938816B1 (https=)
JP (2) JP2007524633A (https=)
AT (2) ATE478663T1 (https=)
AU (1) AU2004258867B2 (https=)
CA (1) CA2529507C (https=)
DE (2) DE602004012279T3 (https=)
DK (1) DK1653943T4 (https=)
ES (2) ES2351581T3 (https=)
PL (1) PL1653943T6 (https=)
PT (1) PT1653943E (https=)
SI (1) SI1653943T1 (https=)
WO (1) WO2005009434A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
AU2002360335A1 (en) * 2001-11-01 2003-05-12 The Regents Of The University Of Michigan Small molecule inhibitors targeted at bcl-2
DE602004012279T3 (de) 2003-06-25 2010-07-15 The Burnham Institute, La Jolla Katecholderivate zur behandlung von krebs
EA011218B1 (ru) 2004-03-25 2009-02-27 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Сокристаллы госсипола и их применение
US20060144723A1 (en) * 2004-11-02 2006-07-06 Mary Fuller Device for securing valuables
WO2009045410A1 (en) * 2007-10-01 2009-04-09 Ascenta Therapeutics, Inc. Process for preparing r-gossypol l-phenylalaninol dienamine
AU2008311827A1 (en) * 2007-10-19 2009-04-23 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
FR2924712B1 (fr) 2007-12-06 2012-12-21 Univ Maine Derives du gossypol et de l'apogossypol, leurs preparations et leurs applications
GB0725077D0 (en) * 2007-12-21 2008-01-30 Univ Murcia Antifolate com[ounds for the treatment of melanoma
WO2009126172A1 (en) * 2008-04-11 2009-10-15 The Trustees Of Columbia University In The City Of New York Resistance to polyphenon e due to increased bcl-2 expression
US20110144125A1 (en) * 2008-08-14 2011-06-16 The Uab Research Foundation Anti-Arrhythmia Agents, Methods of Their Use, Methods of Their Identification and Kits Therefore
US8487131B2 (en) 2009-04-15 2013-07-16 Sanford-Burnham Medical Research Institute Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
BRPI1016102A2 (pt) 2009-04-15 2015-09-01 Sanford Burhnham Medical Res Inst Inibidores de proteínas anti-apoptótica baseados em naftaleno
WO2011017096A2 (en) * 2009-08-04 2011-02-10 Mayo Foundation For Medical Education And Research Methods of treating hematologic cancers
KR20120060234A (ko) 2009-10-08 2012-06-11 샌포드-번햄 메디칼 리서치 인스티튜트 항암제로서의 아포고시폴론 유도체
EP2956470A4 (en) * 2013-02-15 2016-12-07 Univ Michigan Regents COMPOSITIONS AND METHODS RELATED TO PREVENTING DOT1L RECRUITMENT BY MLL FUSION PROTEINS
US9655998B2 (en) 2014-08-07 2017-05-23 Cook Medical Technologies Llc Encapsulated drug compositions and methods of use thereof
US11241520B2 (en) 2014-08-07 2022-02-08 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US9180226B1 (en) 2014-08-07 2015-11-10 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US9750716B2 (en) * 2015-03-19 2017-09-05 Wendy Anne Epstein Compounds and forms of treatment for female sexual disorders
RU2654711C1 (ru) * 2017-07-10 2018-05-22 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, обладающее апоптоз-индуцирующей активностью
KR102432499B1 (ko) * 2018-04-20 2022-08-12 나이키 이노베이트 씨.브이. 플레이트들 및 개재된 유체 충전 블래더를 구비하는 솔 구조체 및 제조 방법
CN110128290B (zh) * 2019-05-10 2022-04-29 江苏耐雀生物工程技术有限公司 红倍酚苯甲酰肼衍生物、中间体、制备方法及其应用
CA3155694A1 (en) * 2019-09-24 2021-04-01 Genetec Inc. Intermediary device for daisy chain and tree configuration in hybrid data/power connection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
US5804567A (en) * 1996-07-18 1998-09-08 Cancer Institute (Hospital), Chinese Academy Of Medical Sciences Method of increasing the effectiveness of anti-metabolites
JPH1036260A (ja) * 1996-07-18 1998-02-10 Mitsui Norin Kk 抗ガン剤の効力増強方法
US6428818B1 (en) 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
WO2002047673A2 (en) * 2000-12-15 2002-06-20 Wackvom Limited Methods and compositions to treat conditions associated with neovascularization
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
AU2002305769B2 (en) * 2001-05-30 2007-07-19 Georgetown University Small molecule antagonists of Bcl2 family proteins
DE602004012279T3 (de) * 2003-06-25 2010-07-15 The Burnham Institute, La Jolla Katecholderivate zur behandlung von krebs

Also Published As

Publication number Publication date
DE602004012279T2 (de) 2009-07-16
ATE387911T1 (de) 2008-03-15
EP1938816A2 (en) 2008-07-02
EP1653943B3 (en) 2008-07-30
AU2004258867A1 (en) 2005-02-03
EP1938816A3 (en) 2008-08-06
ES2351581T3 (es) 2011-02-08
SI1653943T1 (sl) 2008-08-31
DE602004012279D1 (de) 2008-04-17
DK1653943T4 (da) 2008-12-01
DE602004012279T9 (de) 2010-01-28
JP2007524633A (ja) 2007-08-30
US20120269901A1 (en) 2012-10-25
EP1938816B1 (en) 2010-08-25
CA2529507A1 (en) 2005-02-03
PL1653943T3 (pl) 2008-09-30
PT1653943E (pt) 2008-05-23
DK1653943T3 (da) 2008-06-23
EP1653943A2 (en) 2006-05-10
WO2005009434A3 (en) 2005-06-09
ES2303096T7 (es) 2009-06-18
US8367644B2 (en) 2013-02-05
ATE478663T1 (de) 2010-09-15
ES2303096T3 (es) 2008-08-01
PL1653943T6 (pl) 2009-02-27
US20050027000A1 (en) 2005-02-03
JP2012025767A (ja) 2012-02-09
WO2005009434A2 (en) 2005-02-03
US7812058B2 (en) 2010-10-12
DE602004028880D1 (de) 2010-10-07
US20110111057A1 (en) 2011-05-12
DE602004012279T3 (de) 2010-07-15
AU2004258867B2 (en) 2010-02-18
EP1653943B1 (en) 2008-03-05

Similar Documents

Publication Publication Date Title
US8367644B2 (en) Methods and compounds useful to induce apoptosis in cancer cells
Seervi et al. ROS mediated ER stress induces Bax-Bak dependent and independent apoptosis in response to Thioridazine
Koşar et al. Synergic effects of doxorubicin and melatonin on apoptosis and mitochondrial oxidative stress in MCF-7 breast cancer cells: involvement of TRPV1 channels
EP2205088B1 (en) Naphthalene-based inhibitors of anti-apoptotic proteins
Xie et al. Capsaicin and dihydrocapsaicin induce apoptosis in human glioma cells via ROS and Ca2+‑mediated mitochondrial pathway
WO2008134474A2 (en) Compositions and methods including cell death inducers and procaspase activation
Kim et al. Pyrrolidine dithiocarbamate and zinc inhibit proteasome-dependent proteolysis
WO2009026163A1 (en) Compositions and methods for inhibiting growth and metastasis of melanoma
Qiu et al. Synthesis and evaluation of asymmetric curcuminoid analogs as potential anticancer agents that downregulate NF-κB activation and enhance the sensitivity of gastric cancer cell lines to irinotecan chemotherapy
Liu et al. An autophagy-dependent cell death of MDA-MB-231 cells triggered by a novel Rhein derivative 4F
Zhang et al. Curcumin analog, WZ37, promotes G2/M arrest and apoptosis of HNSCC cells through Akt/mTOR inhibition
US9682060B2 (en) Small molecules that induce intrinsic pathway apoptosis
Lai et al. Phenethyl isothiocyanate and irinotecan synergistically induce cell apoptosis in colon cancer HCT 116 cells in vitro
Xu et al. A novel synthesised STAT3 inhibitor exerts potent anti‐tumour activity by inducing lysosome‐dependent cell death
Qiu et al. ZGDHu-1 promotes apoptosis of chronic lymphocytic leukemia cells
US20090163577A1 (en) METHODS AND COMPOSITIONS FOR ANTAGONIZING ANTI-APOPTOTIC Bcl-2-FAMILY PROTEINS
US11512073B2 (en) Benzimidazole derivatives, pharmaceutical composition comprising the same, and use thereof
Meng et al. Direct targeting of GLUT1 in cancer: A decade of inhibitor discovery and medicinal chemistry insights
Lee et al. CLC604 preferentially inhibits the growth of HER2-overexpressing cancer cells and sensitizes these cells to the inhibitory effect of Taxol in vitro and in vivo
KR100961688B1 (ko) 다중약물내성 암세포에 유용한 항암제
EP3600433B1 (en) An agent that increases the expresssion of the bcl2-associated agonist of cell death for the treatment of cancer
WO2013028866A1 (en) Therapeutic compounds and methods

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170627